



## 33<sup>rd</sup> Annual Cancer Progress Conference, May 10<sup>th</sup> – 12<sup>th</sup> 2022

### DAY ONE: MAY 10, 2022

9:30 – 9:45 am

#### Opening Remarks

Jeffrey M. Bockman, PhD, EVP, BioConsulting, Head of Oncology, Humanity

9:45 – 11:00 am

#### Patients Front and Center

Cancer patients have always been front and center, but often for their scientific and treatment importance. What if the world valued the person with cancer as much as they did the disease that afflicts those patients? Listen to cancer survivors, advocates, and industry voices discuss how and when to engage patients in developing therapies for all patient groups. The panel will highlight the challenges and opportunities to make treatments appropriate and accessible for all. By the end of this conversation, attendees may come away with a better understanding of how to structure more ideal cancer treatments and trials so the person being treated is front and center.

**Moderator:** T.J. Sharpe, melanoma survivor, Patient Engagement Program Manager, Medidata Solutions

#### Panelists:

- David Downs, DLBCL survivor, patient advocate
- Ceinwen Giles, DLBCL survivor, Founding Director, Shine Cancer Support, and Chair, NHS Cancer Programme Patient and Public Voices Forum
- Brian Leyland Jones, MB BS, PhD, CMO, National Foundation for Cancer Research
- Michael Parisi CEO, Guidemark Health
- Karen Peterson, TNBC survivor, Founder, Karen's Club
- LaShell Robinson, Director, Diversity and Inclusion in Clinical Trials, Takeda

11:00 am – 12:00 pm

#### How to Catch and Treat Cancer Early

Sequential liquid biopsies are transforming cancer care and management (Turner: "The future of liquid biopsy" The Lancet Oncology, 2020).

However, the challenges of implementing liquid biopsies as a tool for early detection were elegantly described in Swanton's Nature Reviews of Oncology, 2018: "Early-stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection" This panel will update current progress on "the holy grail": an annual affordable test to detect cancer at its earliest stages as part of an annual physical examination. The next obvious challenge will be administration of therapies to treat (and hopefully destroy) malignant subclones before the cancer is detected by current conventional methods.

**Moderator:** Brian Leyland Jones, MB BS, PhD, CMO, National Foundation for Cancer Research

#### Panelists:

- Peter Bach, MD, CMO, Delfi Diagnostics
- Kapil Dhingra, MB, BS, Managing Member, KAPital Consulting LLC
- Colin Hill, CEO and Co-Founder, GNS Healthcare
- Christoph Lengauer, PhD, MBA, Partner, Third Rock Ventures; Thrive/Exact Sciences
- John Sninsky, UCSF Clinical & Translational Science Institute, Catalyst Advisor, Diagnostics, CSO, CareDx

12:00 – 1:00 pm

**Keynote Lunch Address: "Cancer Vaccination: where it fits and what is holding us back"?**

**Speaker:** Lisa H. Butterfield, PhD, Vice President, R&D; Parker Institute for Cancer Immunotherapy; Adjunct Professor, Microbiology and Immunology, UCSF

Cancer vaccination has been developed to promote antitumor immunity in vivo. Many platforms, target antigens and approaches have been tested clinically, but robust clinical efficacy has been minimal. Cancer vaccination is currently being tested in earlier stages of disease and in combination settings. In a natural immune response, the dendritic cell takes up, processes and presents antigens to T cells, and instructs their differentiation. Lessons learned from cancer vaccine clinical trials, including those based on dendritic cells, will be presented

1:00 – 2:15 pm

**State of the Art in Immuno-Oncology: Beyond PDx Inhibitors – or Not So Much**

We have now had a decade of R&D directed towards improving on the applicability and activity of combinations with checkpoint inhibitors (CPIs). There have been many ups and downs, and a few surprises along the way, not the least of which is the combination value of CPIs with chemotherapy and with MTKIs, but not so much with other IO agents. While this may be finally about to change with TIGIT, LAG3, and IL-2 programs to name a few marquee examples, questions still remain on when, where, what and how best to combine CPIs. This session brings together a stellar, and large, cats of experts across the BioPharma industry, from academic researchers and clinical trialists to biotechs to large pharma, to have a dialogue, maybe even a debate, on this complex and fascinating topic.

**Moderator:** Jeffrey M. Bockman, PhD, EVP, BioConsulting, Head of Oncology, Lumanity

**Panelists:**

- Jennifer Buell, PhD, President & CEO, MiNK Therapeutics
- Michael A Curran, PhD, Associate Professor, Dept. of Immunology
- Björn Frendeus, PhD, CSO, BioInvent
- Axel Hoos, MD, PhD, CEO, Scorpion Therapeutics
- Andrew Pierce, PhD, VP of Translational Biology, Crescendo Biologics Ltd
- Peter Sandor, MD, MBA, SVP, Primary Focus Lead Immuno-oncology, Astellas
- Emmett Schmidt, MD, PhD, VP, Clinical Oncology, Lead, External Collaborations Oncology Early Development, Merck and Co
- Dmitriy Zamarin, MD, PhD, Translational Research Director, Gynecologic Medical Oncology, Memorial Sloan Kettering Cancer Center
- Mai-Britt Zocca, PhD, CEO, IO Biotech

**2:15 – 3:15 pm**

**The Latest Potential “Paradigm-Shifters”**

Innovation is not lacking among oncology biotechs. And, by and large, nor has access to potential capital been so much of an issue (at least until recently). But there is a significant gulf between the biologic and platform innovations and the prosecution of such novel programs through the clinic and into the hands of Oncologists and into patients who so desperately need them. This can start with how best to tell the story of the value proposition and the “so what” to rise above the noise and enable initial funding, to smart clinical development strategy to even provisionally outline a path to value inflection and to proof of relevance if not to the market. This session will explore the lessons learned from a diverse set mostly early-ish stage biotechs as they have navigated the investing, partnering and clinical trial waters to advance their exciting agents and platforms forward.

**Moderator:** Jeffrey M. Bockman, PhD, EVP, BioConsulting, Head of Oncology, Lumanity

**Panelists:**

- Dave Altreuter, PhD, CTO, hC Bioscience
- Jacob Becraft, PhD, CEO and Co-Founder, Strand Therapeutics Inc.
- Nicholas A. Boyle, PhD, CEO, Abintus Bio, Inc
- Livija Deban, PhD, CSO, Prokarium
- Leonard A. Farber, MD, Chief Clinical and Medical Affairs Officer, Nanobiotix
- Axel Hoos, MD, PhD, CEO, Scorpion Therapeutics
- Dora Mitchell, PhD, SVP of Operations/Chief of Staff, Interius Biotherapeutics
- Peter Smith, PhD, CEO, MyriO Therapeutics

**3:15 – 4:15 pm**

**ADC “The Next Generation”**

ADCs are having yet another resurgence, driven now by the phenomenal success of ENHERTU, as well as significant innovation in antibody engineering, linker technology, and a diversifying range of conjugates from cytokines to PROTACs. The clinical benefit that can be achieved, even in what many had thought a crowded space with a very high bar around pursuing HER2 proves once again that Oncology is not limited to only incremental advances, but true game-changers can be delivered on even in what have been thought to be well-trodden therapeutic modalities. The example of ENHERTU underscores the need for careful deliberation around clinical path, the development of TPPs, and further raises the bar now for the next HER2-targeting program, whether bispecific or cell therapy or next gen modality. And this idea applies broadly as companies look to bring their novel ADC products into well-validated and highly competitive spaces. With this panel of experts, we will have an engaging dialogue around these opportunities and challenges.

**Moderator:** Jeffrey M. Bockman, PhD, EVP, BioConsulting, Head of Oncology, Lumanity

**Panelists:**

- Gilles Gallant, MD, BPharm PhD FOPQ, Senior VP, Global Head, Oncology Development, Daiichi-Sankyo
- Seema Kantak, PhD., Senior Vice President, Biotherapeutics, Exelixis
- Hans-Georg Lerchen, PhD, CSO, Vincerx
- Timothy Lowinger, PhD, CSO, Mersana Therapeutics
- Bilal Piperdi, VP of Clinical Development, Gilead Sciences, Inc.
- Matt Robinson, PhD, SVP of R&D, Immunome

4:15 -5:15 pm

**Biotech Corporate Strategy: Inflecting Value - Partnering Versus Go It Alone**

Biotech's must keep their options open as they navigate their programs and platform through investment rounds and prospective partner scrutiny. Strategizing and considering the tactical needs, by intent or by need, to move ahead with commercialization may provide more leverage in discussions with partners. Issues of ex-US deals, raising dilutive or non-dilutive capital, scenario planning for success and for failure in clinical trials, all can help in the event of readouts exceeding or missing expectations. This panel will hear from those who have been there and done it in terms of commercializing their lead asset, are doing it as we speak, or are building scenarios for that eventuality, whether by choice or necessity

**Moderator:** Beth Fordham-Meier, VP, BD and Jeffrey M. Bockman, PhD, EVP, Head of Oncology, BioConsulting, Lumanity

**Panelists:**

- PJ Haley, EVP, Commercial, Exelixis
- Bruce Seeley, BA, COO, CTI Biopharma
- Göran Forsberg, PhD, CEO, Cantargia
- Anil Kapur, EVP, Corporate Strategy & CCO, Geron

**Day 1 Cancer Progress 2022 Conference Concludes**

**DAY TWO: MAY 11, 2022**

8:30 -9:00 am

**Fireside Address: "Synergy Is a Four Letter Word."**

Emmett Schmidt, MD, PhD, VP, Clinical Oncology, Lead, External Collaborations Oncology Early Development, Merck and Co

9:15- 9:30 am

**Opening Remarks: Review of Day 1**

Adan Codina, BioConsulting, Consultant, Lumanity

9:30 – 10:30 am

**When Advances in Biology Crash the Business Model: Moving the Discussion Beyond the Price of Cancer Drugs**

Rapid and dramatic advances in biology are accelerating pressure on the tired old model of cancer drug pricing, which claims every new approved oncology drug as a breakthrough qualifying for six figure pricing, at least in the US. The debate over whether this business model is an appropriate reward for the risks of innovation carries on (with little apparent progress given the brutal impact on public and private payers as well as cancer patients and their families). But simultaneously an array of novel approaches to treating cancer have advanced from clinical de-risking to full approval. Among these are a wide array of adoptive cellular therapies, both autologous and "off the shelf," T-cell engagers, gene therapies and gene editing approaches, and personalized or fully individualized vaccines. Although these approaches differ in many ways, they are typically heavily engineered and, thus, come with a cost of goods problem for which prior conventional small molecule and monoclonal antibody drug platforms have been largely spared. Because many of these therapies carry the promise of durable remission or even cure, their costs and complexities will push the debate well beyond the old discussion of high-priced conventional drugs with very limited impact on survival. As these novel approaches continue to de-risk clinically there is an urgent need for commercial innovation, (spanning a diversity of disciplines including manufacturing, distribution, real world evidence and pricing and care delivery models) to keep pace if the benefits of these advanced therapeutics are to reach patients in need.

**Moderator:** Ed Saltzman, Head, Biotech Strategy, Lumanity

**Panelists:**

- Lew Keltner, MD, PhD, CEO, Epistat
- Dawn Lee, CSO, HEOR, Lumanity
- Roger Longman, Founder & Chairman, Real Endpoints
- Derrell Porter, MD, CEO and Founder, Cellevolve
- Burt Zweigenhaft, Managing Partner, Upstream Partners Inc.

**10:30 am – 11:30 am**

**What's Hot/What's Not for Startups in the Quasi-Post-Pandemic Oncology World?**

This panel will bring a diverse set of perspectives on the current climate for Oncology biotechs and investors from those who have taken companies from investment thesis to exit, deal-makers, board members, VCs and foundations. Various dogmas will be discussed, including buying on hype and selling on data to the recent changes in regulatory guidance (such as Optimus) that might lead one to bemoan the added costs, timelines and risk of early clinicals but could also be reframed as “drug development in Oncology was too easy.” Related to this is the opinion that the current state of affairs is a self-inflicted wound of too much hype and overinflated valuations. Given the downturn in biotech, even reasonable data has led to stocks going down, given the heightened expectations—only exceptional data prevents one from being crushed. Which raises several questions: how should companies tell their story to not overhype, how does one balance biologic risk versus modality risk versus other risks (like competitive landscape and differentiation), and given the sheer number of Oncology biotechs hawking their wares, have there been too many companies?

**Moderator:** Mark Simon, Partner, and Co-Founder, Torreya

**Panelists:**

- Kapil Dhingra, MB, BS, Managing Member, KAPital Consulting LLC
- Joel Drewry, PhD, Principal, Versant Ventures
- Asthika Goonewardene, Managing Director Equity Research, Truist Securities
- Anna Turetsky, PhD, Principal, Venture Investments, The Mark Foundation for Cancer Research

**11:30 am – 12:30 pm**

**Biotech versus Pharma Perspectives – Clinical Development Strategy**

Regardless of size, companies are always balancing speed and the need for data: what is enough or POC (for internal decision making and external stakeholders), when is randomization needed, what is the Go/No Go trigger, is accelerated approval possible? With regulatory changes, standard are being raised, so for early biotechs it is what do I need to show to get to my next funding or to interest partners. And still, the needs of the patient are paramount and while one doesn't want reckless development, too fast should not become too slow. And in the confluence of regulatory changes and biotech downturn, one needs to be more careful, it may take more patients, more time, and more money. This session will hear from experienced drug developers in biotech and large Pharma, on the old and new challenges. Additional questions like what is the internal bar, how much differentiation is necessary, what role can surrogate endpoints play, what can be done with dosing/sequencing, how do the experimental models help in all this, etc. Finally, how do these issues differ for small molecules versus biologics, precision medicine agents versus immunotherapies.

**Moderator:** Vicki Goodman, MD, EVP, Product Development and Medical Affairs and CMO, Exelixis

**Panelists:**

- Andres McAllister, MD, PhD, CMO, BioInvent
- Fatima Rangwala, MD, PhD, VP of Clinical Development, Shattuck Labs, Inc.
- Mike Rothenberg, MD, PhD, Head of Early Oncology Development and Clinical Research for Pfizer Oncology R&D and for Pfizer Boulder R&D
- Peter Sandor, MD, SVP, Primary Focus Lead Immuno-oncology, Astellas

12:30 – 1:30 pm

**Break for Lunch**

1:30 – 2:30pm

**Cancer Vaccines Redux: mRNA, Oncolytic Viruses, Or Good Old-Fashioned Peptides – Is It the Target(s), Immunization Platform, Clin Dev Strategy, or All of the Above?**

Cancer vaccines have one of the longest histories in the field of Immunotherapy, going back to the days when this was known as Tumor Immunology. The field has driven, and benefitted from, advances around target/antigen identification, adjuvants, and immunization platforms. But what has really enabled the field over the past decade has been the approval of the checkpoint inhibitors, unlocking the immunosuppressive tumor microenvironment (TME) and allowing immune cells to see and react to exogenous (and/or endogenous) antigens. And yet, while the experimental models continue to demonstrate great preclinical proof of concept, the translation in clinical trials into patient benefit, not just immune responses, has been modest at best (with only one approved vaccine here, Provenge, approved a decade ago). This begs the question of why – why have the responses in animal models not been able to be recapitulated in cancer patients? This session will discuss the various possible reasons and how the industry can best obviate these stumbling blocks, in order to finally see cancer vaccines, realize their true potential.

**Moderator:** Jeffrey M. Bockman, PhD, EVP, BioConsulting, Head of Oncology, Lumanity

**Panelists:**

- Jens Bjorheim, MD PhD, CMO, Ultimovacs AB
- Richard Gaynor, MD, President, Research & Development, BioNTech US
- Victor Levitsky, CSO, Targovax
- Christophe Queva, PhD, CSO, Oncorus Inc.
- Katia Schlienger, MD, PhD, SVP & Global Head, Immuno-Oncology Clinical R&D, Hookipa Pharma, Inc.
- Lauren Wood, MD, PhD, CMO, PDS Biotechnology Corporation

2:30 – 3:30pm

**Does RNA Rule the World?**

The last several years have demonstrated the versatility and adaptability of therapeutic platforms that target RNA or where RNA is the therapeutic payload. These nucleic acid therapeutics are biologically tractable and can be designed by simply typing in the complementary sequence of a target gene or mRNA of interest into a mechanical synthesizer that can manufacture pharmaceutical grade oligonucleotides, or biologically express RNA to clinical scale. However, delivery to the affected tissues has been the major barrier to achieving clinical therapeutic potential for as unmodified RNA is short-lived due to nuclease degradation and targeting an affected cell, having that cell take up the therapeutic and release the RNA into its cytoplasm has plagued the field. To overcome delivery barriers, chemical modifications, GalNAc receptor targeted conjugates and Lipid Nanoparticles (LNPs), have facilitated antisense and siRNA therapies to access to vital organs such as the liver and enabled the rapid development and emergency use authorization of a new class of vaccines for the COVID19 pandemic (BioNTech/Pfizer and Moderna). These successes have not only accelerated the advancement of nucleic acid chemistries, formulation, manufacturing and enabling delivery technologies but also created >\$130B in revenue in product sales over the past two years. Now that these BioPharma firms are cash-rich and in need of new therapeutic opportunities beyond infectious disease and genetic liver diseases, they see oncology as an attractive adjacency. The goal is to open up oncology opportunities by addressing undruggable oncogenes and tumor driver mutations, induce apoptosis and potentiate the antitumor immune response. Today's panel will discuss recent advances on both the RNA therapeutic payloads and enabling delivery technologies and potential as anticancer strategies.

**Moderator:** Michael C. Rice, MS, MBA, SVP, BioConsulting, Advanced Therapeutics and Rare Diseases, Lumanity

**Panelists:**

- Jacob Becraft, PhD, CEO, Co-founder, Strand Therapeutics
- Dietrich A. Stephan, PhD, Chairman and CEO, NeuBase Therapeutics
- Maria Luisa Pineda, PhD, Chief Executive Officer and Co-Founder, Envisagenics, Inc.
- Leslie Williams, Co-Founder, President & CEO, hC Bioscience, Inc.

**3:30 – 4:30 pm**

**Degraders & Beyond: The Rise of Diverse Heterobifunctional Molecules**

Targeted protein degradation is an emerging approach to “drug the undruggable”.

After 30 years of academic work to understand the Ubiquitin pathway and Proteasomal degradation of proteins, biotech and pharma are funding multiple programs to target cancer causing proteins.

This panel will address novel biotech approaches to protein degradation, including early oncology clinical data, and pharmaceutical portfolios of approaches to targeted protein degraders

**Moderator:** Jeremy Goldberg, Operating Partner, Arsenal Capital Partners

**Panelists:**

- Adam Crystal, MD, PhD, CMO, C4 Therapeutics
- Eric Fischer, PhD, Director, Center for Protein Degradation, Dana-Farber Cancer Institute
- Dan Grau, CEO, Avilar Therapeutics
- Greg Hollingworth, co-leader of TPD, Novartis Institutes for BioMedical Research
- Peter Park, CSO, Orum Therapeutics
- Mark Rolfe, Ph.D, SVP, R&D, Oncogenesis Thematic Research Center, Bristol Myers Squibb
- Anil Vasudevan, PhD, Senior Director, Abbvie

**Day 2 Cancer Progress 2022 Conference Concludes**

**DAY THREE: MAY 12, 2022**

**8:00 - 8:15 am**

**Opening Remarks: Review of Day 2**

Viraj Parekh, PhD, Managing Consultant, BioConsulting, Associate Consultant, Lumanity

**8:15 – 9:00 am**

**Keynote Address: "Overcoming barriers to CAR-T cell therapy for solid tumors"**

**Speaker:** Shivani Srivastava PhD, Assistant Professor Human Biology Division, Fred Hutchinson Cancer Research Center

Immunotherapy using T cells engineered to express chimeric antigen receptors (CARs) has induced dramatic responses in patients with advanced hematological malignancies, representing one of the most remarkable therapeutic advances in the past decade. This success has raised expectations that CAR-T cells can be applied to treat common epithelial malignancies, which cause the greatest mortality, but numerous obstacles must be overcome to achieve the success observed in hematologic cancers. Here, we discuss the factors limiting CAR-T cell activity in solid tumors, including heterogeneity of tumor antigen expression, T cell dysfunction in the tumor microenvironment, and poor persistence of infused CAR-T cells, and discuss how advances in genetic engineering, synthetic biology, and improved tumor models that faithfully recapitulate obstacles in human tumors, may offer potential solutions.



**9:00 – 10:00 am      Into the Unknown – Bringing New Modalities into Solid Tumors**

Continuing to build upon the discussion initiated by our Keynote Address from Dr. Shivani, this panel will explore considerations with respect to positioning of cell-based and other emerging immunotherapy platforms in solid tumors, an endeavor that generally presents a combination of commercial opportunity and clinical risk. Topics to be addressed by this panel include the current state of play, alignment of science with evolving unmet needs, and perceived paths towards value inflection within different solid tumor markets.

**Moderator:** Joel Sandler, PhD, Principal, BioConsulting, Cancer Cell Therapy Practice Lead, Lumanity

**Panelists:**

- Andrew Allen, MD, PhD, President & CEO, Gritstone Bio
- Mark Berger, MD, CMO, Genprex Inc.
- Frank Borriello, MD, PhD, Scientific Founder & CEO, Alloplex Biotherapeutics Inc.
- Sabrina Kuttruff-Coqui, PhD, VP Business Planning & Portfolio Strategy, Immatics
- Shivani Srivastava PhD, Assistant Professor Human Biology Division, Fred Hutchinson Cancer Research Center
- Tom Wilton, CBO, Carisma Therapeutics Inc.

**10:00 – 11:00 am      Growing Pains – Navigating the Precipitous Path Towards Commercialization**

It's time to put your money where your mouth is. Cell therapies are entering the clinic en masse. What's more, an increasing number of programs are potentially headed towards market authorization and approval. With massive amounts of capital (investments, partnering dollars) allocated specifically towards the promise of cell therapy in already crowded competitive arenas, the coming months and years will be critical for both the clinical and commercial validation of these new technologies. The extent to which cell therapy as a class will have broad and deep utility will be determined by the ability of these early programs to provide meaningful returns for patients, providers, payers, partners, and investors. This panel will delve into the 'nice problem to have' for a field that's growing up quick.

**Moderator:** Joel Sandler, PhD, Principal, BioConsulting, Cancer Cell Therapy Practice Lead, Lumanity

**Panelists**

- Michael DeRidder, PhD, SVP, Corporate Strategy and New Product Planning Catamaran Bio
- Steven J Klein, PhD, MBA, CBO, Epiteopea
- Peter Sandor, MD, SVP, Primary Focus Lead Immuno-oncology, Astellas

**11:00 am – 12:00 pm      Tortoises and Hares – De-risking Strategies Towards Multiplexed Candidates**

A company's product portfolio should tell the story about how well leadership understands its value proposition and has set about de-risking what may be transformative but as yet unproven technology. The need to systemically de-risk becomes particularly pressing when building upon validated approaches with unique or multiplexed engineering of cell therapy candidates. Advancing through a series of increasingly sophisticated clinical candidates can be done too slowly or too quickly, and the markets make their determination only with the benefit of hindsight. Regardless, R&D must be informed by a forward-looking positioning strategy, and we will discuss some of the key considerations to adopt and pitfalls to avoid when advancing novel engineering components or combinations thereof.



**Moderator:** Michael C. Rice, MS, MBA, SVP, BioConsulting, Advanced Therapeutics and Rare Diseases, Lumanity

**Panelists:**

- Gregory Block, PhD, Senior Vice President, Corporate Development, Notch Therapeutics
- Eliot Bourk, PhD, Chief Business Officer and Head of External Innovation, Chimeric Therapeutics
- David C. White, PhD, CEO, Modulari-T Biosciences
- Paul D. Rennert, President & CSO, Aleta Biotherapeutics

**12:00 – 1:00 pm**

**Break for Lunch**

**1:00 – 2:00 pm**

**Selling the Cell – Cost-benefit Considerations for Complex Therapeutics**

While there are only two sides to the cost-benefit equation, each has a number of components baked in. On the cost side, increasingly sophisticated cell-based and other immunotherapies can be expensive to manufacture and deliver, and supportive and other resource-based care costs incurred by providers must also be factored in. Different markets (e.g., US vs. UK and different EU regions) have adopted varying stances, but all are applying an increasingly restrictive stance on how much companies can charge. On the benefit side, therapeutic candidates must outperform in their indications both against current and evolving standards of care. While clinical performance is difficult to predict beforehand, optimal positioning strategy is required to ensure maximal unlocking of value from these complicated therapeutic technologies in order to ensure healthy margins, both in cancer patients and the balance sheet.

**Moderator:** Joel Sandler, PhD, Principal, BioConsulting, Cancer Cell Therapy Practice Lead, Lumanity

**Panelists:**

- Gregory Fiore, MD, CEO, Exacis Biotherapeutics
- Daniel Gladwell, Chief of HTA Strategy, HEOR, Lumanity
- Jason Litten MD, formerly CMO at Artiva Biotherapeutics
- Peretz Partensky, PhD, CEO, ImmuneBridge
- Ramon V. Tiu, MD, Head of Oncology Cell Therapy Development, Takeda
- Satish Valluri, CAR-T Global Market Access Head, Janssen

**2:00 – 3:00 pm**

**Building on Success – Clinical and Commercial Dynamics in Heme Malignancies and Hematopoietic Transplantation**

Cell therapies have achieved arguably the greatest clinical success in heme malignancies where hematopoietic stem cell transplantation (HSCT) has already long been a validated component of the treatment algorithm. That these programs are generating interest among patients and driving continued investment in next-gen technologies speaks both to the fact that these novel approaches are building upon an already strong foundation and one that is ripe for disruption with improved clinical performance or logistical attributes. This panel will discuss how cell therapy technologies are being adopted in heme malignancies where transplant is used, and how adoption of different modalities might evolve over time and with respect to one another.

**Moderator:** Michael C. Rice, MS, MBA, SVP, BioConsulting, Advanced Therapeutics and Rare Diseases, Lumanity

**Panelists:**

- Robert Ang, MBBS, MBA, CEO, Vor Bio
- Francesco Galimi, MD, PhD, Senior VP, CMO, Adicet Bio
- Lore Gruenbaum, PhD, VP of Therapy Acceleration Program, Leukemia & Lymphoma Society
- Kristi Jones, CEO, NexImmune, Inc.
- Mythili Koneru, MD, PhD, CMO, Marker Therapeutics Inc.
- Charles Nicolette, PhD, President & CEO, CoIMMUNE Inc.

**3:00 – 4:00 pm**

**Tools of the Trade – Strategic Positioning of Emerging Cell Types, Target Discovery Engines, and Gene Engineering Tools**

With so many high-profile deals and fundraising rounds, its easy to lose sight of the technologies themselves and how they're quickly transforming the ways in which even the term 'therapeutic' can be defined. Cell therapy in particular is a place for the biochemical equivalent of 'gear-heads', those of us who enjoy getting in the weeds on different cell types, enabling modifications, and discovery engines. The truly successful among us, however, are those that can quickly pull out the 'so what?' from such sophisticated technologies in a way that resonates with key stakeholders such as investors, partners, and patients. This panel will walk the walk across that unwieldy but all-too-important tightrope between the technology and applications in which it must inflect value.

**Moderator:** Michael C. Rice, MS, MBA, SVP, BioConsulting, Advanced Therapeutics and Rare Diseases, Lumanity

**Panelists:**

- Richard Boyd, PhD, CSO, Cartherics
- William Ho, Director, President, CEO, and Co-Founder, In8bio
- Reagan Jarvis, CEO and Scientific Founder, Anocca
- Lynnet Koh, CEO & Founder, Targazyme, Inc.
- Derek Ostertag, PhD, Co-Founder and SVP R&D

**4:00 – 5:00 pm**

**Battle of the Modalities: The Sequel to the Sequel – Revenge of the Nerds**

Last year we heard slam poetry in defense of cell therapy against other modalities. What'll we see this time around? Tune in to find out.

**Panelists:**

- Jeff Bockman, PhD, EVP, Head of Oncology, Lumanity
- Viraj Parekh, PhD, Sr Consultant, Oncology Lead, Lumanity
- Michael C. Rice, MS, MBA, SVP, Advanced Therapeutics and Rare Diseases, Lumanity
- Joel Sandler, PhD, Principal, Cancer Cell Therapy Practice Lead, Lumanity

**Cancer Progress 2022 Conference Concludes**